File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities

TitleCost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities
Authors
KeywordsRespiratory syncytial virus
Acute lower respiratory infection
Maternal immunisation
Monoclonal antibody
Paediatric immunisation
Issue Date2021
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2021, v. 39, p. 5490-5498 How to Cite?
AbstractBackground: New monoclonal antibodies (mAbs) and vaccines against RSV with promising efficacy and protection duration are expected to be available in the near future. We evaluated the cost-effectiveness of the administration of maternal immunisation (MI), infant mAb (IA) and paediatric immunisation (PI) as well as their combinations in eight Chinese cities. Methods: We used a static model to estimate the impact of these preventive interventions on reducing the burden of RSV-ALRI in twelve monthly birth cohorts from a societal perspective. In addition to year-round administration, we also considered seasonal administration of MI and IA (i.e., administered only to children born in selected months). The primary outcome was threshold strategy cost (TSC), defined as the maximum costs per child for a strategy to be cost-effective. Results: With a willingness-to-pay threshold of one national GDP per capita per QALY gained for all the cities, TSC of year-round strategies was: (i) US$2.4 (95% CI: 1.9-3.4) to US$14.7 (11.6-21.4) for MI; (ii) US$19.9 (16.9-25.9) to US$144.2 (124.6-184.7) for IA; (iii) US$28.7 (22.0-42.0) to US$201.0 (156.5-298.6) for PI; (iv) US$31.1 (24.0-45.5) to US$220.7 (172.0-327.3) for maternal plus paediatric immunisation (MPI); and (v) US$41.3 (32.6-58.9) to US$306.2 (244.1-441.3) for infant mAb plus paediatric immunisation (AP). In all cities, the top ten seasonal strategies (ranked by TSC) protected infants from 5 or fewer monthly birth cohorts. Conclusions: Administration of these interventions could be cost-effective if they are suitably priced. Suitably-timed seasonal administration could be more cost-effective than their year-round counterpart. Our results can inform the optimal strategy once these preventive interventions are commercially available.
Persistent Identifierhttp://hdl.handle.net/10722/308036
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLIU, D-
dc.contributor.authorLeung, K-
dc.contributor.authorJit, M-
dc.contributor.authorWu, JT-
dc.date.accessioned2021-11-12T13:41:30Z-
dc.date.available2021-11-12T13:41:30Z-
dc.date.issued2021-
dc.identifier.citationVaccine, 2021, v. 39, p. 5490-5498-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/308036-
dc.description.abstractBackground: New monoclonal antibodies (mAbs) and vaccines against RSV with promising efficacy and protection duration are expected to be available in the near future. We evaluated the cost-effectiveness of the administration of maternal immunisation (MI), infant mAb (IA) and paediatric immunisation (PI) as well as their combinations in eight Chinese cities. Methods: We used a static model to estimate the impact of these preventive interventions on reducing the burden of RSV-ALRI in twelve monthly birth cohorts from a societal perspective. In addition to year-round administration, we also considered seasonal administration of MI and IA (i.e., administered only to children born in selected months). The primary outcome was threshold strategy cost (TSC), defined as the maximum costs per child for a strategy to be cost-effective. Results: With a willingness-to-pay threshold of one national GDP per capita per QALY gained for all the cities, TSC of year-round strategies was: (i) US$2.4 (95% CI: 1.9-3.4) to US$14.7 (11.6-21.4) for MI; (ii) US$19.9 (16.9-25.9) to US$144.2 (124.6-184.7) for IA; (iii) US$28.7 (22.0-42.0) to US$201.0 (156.5-298.6) for PI; (iv) US$31.1 (24.0-45.5) to US$220.7 (172.0-327.3) for maternal plus paediatric immunisation (MPI); and (v) US$41.3 (32.6-58.9) to US$306.2 (244.1-441.3) for infant mAb plus paediatric immunisation (AP). In all cities, the top ten seasonal strategies (ranked by TSC) protected infants from 5 or fewer monthly birth cohorts. Conclusions: Administration of these interventions could be cost-effective if they are suitably priced. Suitably-timed seasonal administration could be more cost-effective than their year-round counterpart. Our results can inform the optimal strategy once these preventive interventions are commercially available.-
dc.languageeng-
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine-
dc.relation.ispartofVaccine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectRespiratory syncytial virus-
dc.subjectAcute lower respiratory infection-
dc.subjectMaternal immunisation-
dc.subjectMonoclonal antibody-
dc.subjectPaediatric immunisation-
dc.titleCost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities-
dc.typeArticle-
dc.identifier.emailLeung, K: ksmleung@hku.hk-
dc.identifier.emailWu, JT: joewu@hku.hk-
dc.identifier.authorityLeung, K=rp02563-
dc.identifier.authorityWu, JT=rp00517-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.vaccine.2021.08.057-
dc.identifier.pmid34454783-
dc.identifier.scopuseid_2-s2.0-85113532303-
dc.identifier.hkuros329533-
dc.identifier.volume39-
dc.identifier.spage5490-
dc.identifier.epage5498-
dc.identifier.isiWOS:000704399700006-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats